Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of “Reduce” from Brokerages

Posted by on Aug 7th, 2026

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has been assigned an average recommendation of “Reduce” from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.20.

A number of brokerages recently commented on FULC. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Friday, July 17th. Citigroup cut Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research report on Tuesday, June 2nd. Truist Financial downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a research note on Tuesday, June 2nd. Finally, Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 2nd.

View Our Latest Stock Analysis on FULC

Insider Buying and Selling at Fulcrum Therapeutics

In other news, Director Alan Ezekowitz sold 18,000 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the transaction, the director owned 10,927 shares of the company’s stock, valued at $39,883.55. The trade was a 62.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 7.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Fulcrum Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Catalio Capital Management LP purchased a new position in Fulcrum Therapeutics in the fourth quarter valued at about $2,277,000. Siren L.L.C. boosted its position in shares of Fulcrum Therapeutics by 20.5% in the first quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock worth $18,024,000 after buying an additional 400,000 shares during the period. Nicholas Investment Partners LP acquired a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at about $2,069,000. Simplify Asset Management Inc. raised its holdings in shares of Fulcrum Therapeutics by 91.8% during the 4th quarter. Simplify Asset Management Inc. now owns 159,674 shares of the company’s stock valued at $1,806,000 after buying an additional 76,440 shares during the period. Finally, First Turn Management LLC acquired a new position in shares of Fulcrum Therapeutics during the fourth quarter worth $21,406,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $3.78 on Friday. The firm has a market capitalization of $288.41 million, a P/E ratio of -3.12 and a beta of 3.05. Fulcrum Therapeutics has a one year low of $2.83 and a one year high of $15.74. The company’s fifty day moving average is $3.75 and its two-hundred day moving average is $6.72.

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, sell-side analysts forecast that Fulcrum Therapeutics will post -0.67 earnings per share for the current fiscal year.

About Fulcrum Therapeutics

(Get Free Report)

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

Featured Articles

Analyst Recommendations for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.